Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Symboli: 002693.SZ
SHZ
6.14
CNYMarkkinahinta tänään
-38.3977
P/E-suhde
-0.7680
PEG-suhde
2.55B
MRK Cap
- 0.00%
DIV Tuotto
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 291.41 | 31.9 | 146 | 77 | |||||||||||||||
balance-sheet.row.short-term-investments | 223.27 | 28.5 | 133.8 | 55.4 | |||||||||||||||
balance-sheet.row.net-receivables | 97.01 | 16.4 | 41 | 33.1 | |||||||||||||||
balance-sheet.row.inventory | 306.61 | 74.3 | 65.4 | 55.2 | |||||||||||||||
balance-sheet.row.other-current-assets | 0.25 | 0.2 | 0 | 0.1 | |||||||||||||||
balance-sheet.row.total-current-assets | 721.6 | 135.2 | 252.4 | 165.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1823.92 | 457.6 | 471.8 | 504.7 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 688.05 | 171.8 | 164.9 | 156.9 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 688.05 | 171.8 | 164.9 | 156.9 | |||||||||||||||
balance-sheet.row.long-term-investments | 44.81 | 10 | 8.8 | 17.3 | |||||||||||||||
balance-sheet.row.tax-assets | 4.76 | 1.5 | 1 | 1 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 83.17 | 27.1 | 12.2 | 9.1 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 2644.71 | 668 | 658.6 | 689.1 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 3366.32 | 803.2 | 911 | 854.6 | |||||||||||||||
balance-sheet.row.account-payables | 61.58 | 17.1 | 15.5 | 17.2 | |||||||||||||||
balance-sheet.row.short-term-debt | 388.3 | 10.1 | 205.3 | 0.3 | |||||||||||||||
balance-sheet.row.tax-payables | 13.4 | 3.7 | 12.8 | 7.2 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 290.02 | 135 | 0 | 167 | |||||||||||||||
Deferred Revenue Non Current | 31.26 | 8 | 7.6 | 8.9 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 11.26 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 9.06 | 2 | 73.6 | 1.8 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 332.55 | 145.7 | 10.7 | 179.4 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-liab | 1177.06 | 285.6 | 330.1 | 287.8 | |||||||||||||||
balance-sheet.row.preferred-stock | 68.85 | 34.4 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 1666.33 | 416.7 | 414.7 | 412 | |||||||||||||||
balance-sheet.row.retained-earnings | -1287.93 | -347 | -296.2 | -305.2 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 501.27 | -0.4 | 87.2 | 82.2 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1044.52 | 367.6 | 307.9 | 292.9 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 1993.04 | 471.5 | 513.5 | 481.8 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 3366.32 | 803.2 | 911 | 854.6 | |||||||||||||||
balance-sheet.row.minority-interest | 196.22 | 46.2 | 67.4 | 84.9 | |||||||||||||||
balance-sheet.row.total-equity | 2189.26 | 517.6 | 580.9 | 566.8 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 3366.32 | - | - | - | |||||||||||||||
Total Investments | 206.63 | 10 | 133.8 | 55.4 | |||||||||||||||
balance-sheet.row.total-debt | 678.32 | 145.1 | 205.3 | 167.3 | |||||||||||||||
balance-sheet.row.net-debt | 610.18 | 141.7 | 193.1 | 145.6 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -63.99 | -8.5 | -40.8 | -79.9 | ||||||||||||||
cash-flows.row.depreciation-and-amortization | 40.38 | 57.5 | 54.3 | 57.1 | ||||||||||||||
cash-flows.row.deferred-income-tax | -3.82 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.stock-based-compensation | 1.42 | 6.9 | 7.2 | -1.2 | ||||||||||||||
cash-flows.row.change-in-working-capital | -10.62 | -4.5 | 14.9 | -12.2 | ||||||||||||||
cash-flows.row.account-receivables | 4.99 | -13.8 | 5.4 | 39.8 | ||||||||||||||
cash-flows.row.inventory | -12.45 | -9.9 | -4.8 | -4.3 | ||||||||||||||
cash-flows.row.account-payables | 0 | 19.6 | 13.8 | -48.9 | ||||||||||||||
cash-flows.row.other-working-capital | -3.17 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.other-non-cash-items | 45.94 | -25.8 | -12.5 | 24.5 | ||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 7.88 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -50.56 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.acquisitions-net | 14.27 | 27 | 21.7 | 53.6 | ||||||||||||||
cash-flows.row.purchases-of-investments | -193.85 | -471 | -256.2 | -637.2 | ||||||||||||||
cash-flows.row.sales-maturities-of-investments | 263.71 | 391.9 | 299.2 | 615.3 | ||||||||||||||
cash-flows.row.other-investing-activites | 13.08 | 0 | 0 | -51.6 | ||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 16.89 | -85.1 | 33 | -71.5 | ||||||||||||||
cash-flows.row.debt-repayment | -92.11 | -12 | -55.3 | -1.8 | ||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.dividends-paid | -7.78 | -11.1 | -9.1 | -9.8 | ||||||||||||||
cash-flows.row.other-financing-activites | 35.64 | 68.1 | 23.8 | 57 | ||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -13.02 | 44.9 | -40.6 | 45.4 | ||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.01 | 0.1 | -0.1 | -0.3 | ||||||||||||||
cash-flows.row.net-change-in-cash | 11.76 | -14.8 | 15.8 | -36.9 | ||||||||||||||
cash-flows.row.cash-at-end-of-period | 68.14 | 6.8 | 21.6 | 5.8 | ||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 56.38 | 21.6 | 5.8 | 42.7 | ||||||||||||||
cash-flows.row.operating-cash-flow | 7.88 | 25.2 | 23.6 | -10.5 | ||||||||||||||
cash-flows.row.capital-expenditure | -50.56 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.free-cash-flow | -42.68 | -7.8 | -8.1 | -62.1 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 197.21 | 235.9 | 274.8 | 320.3 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 68.14 | 74.9 | 88.3 | 81.4 | |||||||||||||||
income-statement-row.row.gross-profit | 129.06 | 161.1 | 186.5 | 238.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 8.41 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 20.73 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 80.37 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0.19 | 0.2 | 63.2 | 69 | |||||||||||||||
income-statement-row.row.operating-expenses | 164.04 | 183.4 | 215.8 | 282.7 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 232.18 | 258.3 | 304.1 | 364.1 | |||||||||||||||
income-statement-row.row.interest-income | 0.04 | 0 | 0.1 | 0.1 | |||||||||||||||
income-statement-row.row.interest-expense | 9.04 | 9.6 | 11.2 | 9 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 80.37 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -58.06 | -50.6 | 15.6 | 2 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0.19 | 0.2 | 63.2 | 69 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -58.06 | -50.6 | 15.6 | 2 | |||||||||||||||
income-statement-row.row.interest-expense | 9.04 | 9.6 | 11.2 | 9 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 32.98 | 52.7 | 57.5 | 54.3 | |||||||||||||||
income-statement-row.row.ebitda-caps | -31.85 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | -87.45 | -73.2 | -24.5 | -42.3 | |||||||||||||||
income-statement-row.row.income-before-tax | -87.26 | -73 | -8.9 | -40.4 | |||||||||||||||
income-statement-row.row.income-tax-expense | -12.63 | -1 | -0.4 | 0.4 | |||||||||||||||
income-statement-row.row.net-income | -63.99 | -50.7 | -8.5 | -40.8 |
Usein kysytty kysymys
Mikä on Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) taseen loppusumma?
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) kokonaisvarat ovat 803248121.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on 96442813.000.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.654.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on -0.103.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on -0.324.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on -0.443.
Mikä on Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on -50741578.370.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 145050750.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 183423820.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 17684279.000.